US/UK/Canada

Share

Contacts

  • Probi
    Ideongatan 1A, 223 70 Lund
    +46(0)46-286 89 20
    https://www.probi.com
  • Anita Johansen

    Interim CEO & VP R&D


    +46 46 286 89 20
  • Basudha Bhattarai Johansson

    VP HR & Sustainability


    +46 46 286 89 20

    • Quotes

    A lot of virus and bacteria enter the body through the mucous membranes, where a majority of our immune system is located. Therefore, we believe that probiotics can play a vital role as delivery carrier.
    Professor Magnus Johansson
    This joint venture is an important step in our commercial efforts to address new and attractive market niches. Even in these turbulent times we see great opportunities to jointly build a successful business, based on our longstanding relationship and confidence in our respective abilities to create scientific and commercial success.
    Tom Rönnlund, CEO Probi
    “We are very excited about the results showing an opportunity to delay the progression of bone loss by using our probiotics in this healthy population, which potentially may lead to a reduced risk for osteoporosis.”
    Ole Søgaard Andersen, CEO of Probi
    We are very happy to initiate this development program together with a strong global partner in OTC. By combining Probi´s probiotic expertise with the pharma company's development resources and regulatory expertise, we will form a very strong team moving forward together.”
    Ole Søgaard Andersen CEO of Probi
    “We are proud to conclude that our largest clinical trial so far has successfully confirmed earlier clinical results. Interestingly, in subjects that did not experience any viral infection during the study period, there was an activation of the immune system measured already after 2 weeks of Probi Defendum® intake, indicating an alert and resilient immune system.”
    Peter Nählstedt, CEO Probi AB
    “It is extremely exciting to launch the new probiotic line - Probi Select™. Through the integration of Nutraceutix, Probi has established a complete probiotic offering with the Probi Premium, Probi Select and Probi LiveBac ranges. Probi is now a true “One stop shop” for any consumer goods company wanting to drive their position in the probiotic market”
    Niklas Bjärum, President Probi USA and Global Sales & Marketing Probi Group.
    I am very excited about this transforming acquisition. Nutraceutix is an excellent match for us. Probi and Nutraceutix have complementary business models, limited customer overlap and share strong entrepreneurial values. The acquision creates a strong platform to continue the growth story in the US and in the global market.
    Peter Nählstedt
    ”There has been strong growth in the North American and Asian probiotic markets the past few years. We now see a growing interest in Europe too, and our new distribution agreements clearly reflect this positive trend
    Niklas Bjärum, Vice President of Marketing & Sales
    Pick a time period -
    Tags ( Active)

    Q1 2024: Steady Progress in a Transitional Year

    Important events during the first quarter · Underlying sales were overall as expected, despite Q1 coming in 12% below Q1 LY (11% adjusted for currency effects) to SEK 152 m (172). The reduction compared to LY is primarily due to positive one-time effects from delayed deliveries in the Americas as a result of a severe snowstorm at the end of 2022. Additionally, APAC was affected by timing shifts in orders during the quarter. · The EBITDA margin amounted to 15% (28). Adjusted for the above-mentioned snowstorm the comparison year margin is 23%. · A new study showing synergistic

    Q2 2023: Weak underlying market in the Americas and EMEA

    Important events during the second quarter · Net sales decreased by 18% (21% adjusted for currency effects) to SEK 144 m (175). · The EBITDA margin amounted to 9% (26) and was burdened by items affecting comparability. Adjusted for these, the EBITDA margin was 17%. · Approval of HEAL9™ in Thailand. Enables further expansion in APAC. · Takeover of distribution of our own brand Probi® in Sweden and entry into Norway with new agreements with pharmacies. · Exclusive distributor of BLIS K12™ and BLIS M18™ ingredients in the US and Canada as of August 1. · New partnership with

    Q4 2022: Fourth quarter impacted by one-off items

    Important events during the fourth quarter · Net sales decreased by 15% (-27% adjusted for currency effects) to SEK 144 m (170) in Q4. Snowstorms in the USA delayed deliveries to the value of SEK 18 m in net sales. · The EBITDA margin amounted to 11% (32) in Q4. Adjusted for the delayed deliveries and one-off items, the EBITDA margin was 24%. · Probi will take over the distribution of its own brand Probi® from April 1, 2023. · Purchase of strain rights from American partners for faster commercialization of spores. · The Board appointed Anita Johansen as Interim CEO. New

    Q2 2022: Solid quarter with exchange rate fueled growth

    Important events during the second quarter · Net sales increased by 10% (-1% adjusted for currency effects) to SEK 175 m (158) in Q2 and amounted to SEK 329 m (329) for H1, which was on a par with previous year (-9% adjusted for currency effects). · The EBITDA margin was 26% (25) in Q2 and 26% (26) in H1. · Stable performance in all regions, strongest quarter since 2020 in APAC. · Increased investments in sales activities and build-up of sales organization in region Americas. · New skincare product based on by-product from production process, contributes to reduced

    Q4 2021: Strong development in EMEA, Americas affected by customer dynamics

    Significant events during the fourth quarter · Net sales decreased by 8% (-9% adjusted for currency effects) to SEK 170 m (185). · The EBITDA margin was 32% (25%). · Strong performance in EMEA and APAC during the quarter, while the Americas continued to be affected by earlier communicated customer dynamics. Significant events during full-year 2021 · Net sales decreased by 8% (-3% adjusted for currency effects) to SEK 658 m (717). · The EBITDA margin was 28% (27%). · Several important partnerships were entered during the year, including Oriflame and Sinopharm Foreign

    Q3 2021: Regional dynamics affecting the quarter

    Significant events during the third quarter · Net sales decreased by 18% (-17% adjusted for currency changes) to SEK 159 m (195) in Q3 and decreased by 8% (-1% adjusted for currency changes) to SEK 488 m (532) for the first nine months of the year. The comparative period was positively affected by non-recurring income of around SEK 15 m. · The EBITDA margin was 27% (32%) in Q3 and 26% (28%) for the first nine months of the year. · Work started with Blis Technologies for the start of production and collaboration in the sales organization and R&D. · First tolerance study of two

    Q2 2019: Favourable growth continues in Q2

    Significant events in the second quarter · Second-quarter net sales amounted to MSEK 180 (153), an increase of 18% (adjusted for currency effects 15%) compared with the second quarter of 2018 · EBITDA for the second quarter amounted to MSEK 57 (43), an increase of 32% compared with the second quarter of 2018 · A successfully completed clinical trial on 326 healthy pregnant women showed that intake of Probi FerroSorb® significantly improved iron status · New product concept launched in the Nordic market, adapted for consumers of all ages, with the products Probi® Baby, Probi®

    Q1 2019: Revenue growth and strong cash flow starts the year

    Significant events in the first quarter · First-quarter net sales rose to MSEK 138, up 16%, or MSEK 19 compared with the first quarter 2018 · EBITDA increased by MSEK 11, up 64% compared with the first quarter 2018 · Early repayment of a bank loan totalling MSEK 60 reflects the strength of Probi’s balance sheet and cash flow · Ongoing launches of Probi® Osteo, for the prevention of bone loss in postmenopausal women. Strong customer interest and several customer launches planned in 2019 Financial overview MSEK Q1 Q1 2018 Full-year 2018

    Q4 2018: Growth in fourth quarter closes the year

    Significant events in the fourth quarter• Fourth-quarter net sales rose to MSEK 163, up 36%, or MSEK 43 compared with the year-on-year period, due to continued recovery from a customer-specific destocking programme• First commercial order after the introduction of Probi’s product to improve bone health in postmenopausal women – Probi® Osteo• Promising initial results from clinical trials to evaluate the effects of Probi’s strains on physical performance and acute stress• Tom Rönnlund appointed new CEO as of January 1, 2019 and Henrik Lundkvist new CFO as of January 7, 2019• Board

    Q3 2018: Probi delivers strong operating performance and appoints new CEO

    Highlights and significant events in the third quarter• Q3 net sales increase to MSEK 169, up 26% or MSEK 35 quarter-on-quarter, driven by improved commercial execution and recovery from a customer destocking program• Probi appoints Tom Rönnlund as new CEO, starting end of 2018, and implements a new, customer-centric organizational structure• Partial early redemption of bank borrowings for a total amount of MSEK 57, reflecting the strength of Probi’s balance sheet, improved margins and cash flows Financial overview MSEK    9M 2018    9M 2017

    Q4 2017: Probi achieves major milestone in expansion of Functional Food business area

    Highlights and significant events in the fourth quarter · Major agreement signed with global FMCG leader to launch Functional Food product in North America in 2019 · Important product launches of FerroSorb® and Probi Select™ in North America start to deliver cross-selling synergies in Consumer Healthcare · Submission of new health claim application to EFSA for iron uptake product FerroSorb® following positive results in supplementary study · Board of Directors and CEO propose that the 2018 Annual General Meeting resolves that no dividends will be paid for the 2017 financial

    Q3 2017: Growth and earnings impacted by a major customer’s destocking

    Highlights and significant events in the third quarter · Continued destocking by major customer, impacting net sales and earnings during the second half of 2017 and first quarter of 2018 · New FerroSorb® and Digestis® FastMelt product launches in Asia and Europe · Extension of Ipsen distribution partnership to Italy · First results of multi-trial programme to develop a new probiotic platform for children show positive and significant results in supporting the immune system and in delaying the onset of gluten intolerance Financial overview MSEK

    Q2 2017: Probi completes integration and ends first half of 2017 with increase in sales and earnings

    Highlights and significant events during the second quarter • Robust growth in sales and earnings despite inventory management at one of the largest customers• Successful completion of integration process, strengthening of marketing and sales organization and finalization of purchase price allocation at Probi USA• Several new distribution agreements in EMEA• Launch of research program targeted at next generation probiotics and prebiotics Financial overview MSEK H1 2017 H1 2016 Full -year

    Q1 2017: Probi continues on its successful growth path

    Highlights and significant events during the first quarter · Significant increase in sales and earnings driven by Nutraceutix acquisition and organic growth · Market launch of patented and clinically documented Probi SelectTM product range in North America · Start of strategic initiatives to increase production capacity and to design a new Group enterprise system (ERP) Financial overview MSEK Q1  Q1 Full-year 2017   2016 2016Net sales 187.4 87.0 443.5Net sales growth, local

    Q4 2016: ACQUISITION COMPLETED, RIGHTS ISSUE SUCCESSFUL AND YET ANOTHER SALES RECORD

    FOURTH QUARTER OF 2016 NET SALES amounted to MSEK 194.0 (35.9), including MSEK 75,6 from acquisitions. · OPERATING PROFIT totalled MSEK 43.6 (3.7). · PROFIT AFTER TAX amounted to MSEK 36.8 (2.7). · PROFIT AFTER TAX PER SHARE was SEK 3.46 (0.30). · CHANGE IN CASH AND CASH EQUIVALENTS amounted to MSEK -864.5 (0.0). The purchase consideration of MSEK 900 for the acquisition was paid on 3 October.               ACCUMULATED 2016 · NET SALES amounted to MSEK 443.5 (215.7), including MSEK 76 from acquisitions. · OPERATING PROFIT totalled MSEK 130.3 (63.1). Operating

    ACQUISITION OF NUTRACEUTIX COMPLETED AND A NEW QUARTERLY SALES RECORD

    THIRD QUARTER OF 2016 · NET SALES amounted to MSEK 89.2 (51.9). · OPERATING PROFIT[1] totalled MSEK 30.7 (16.3). Operating profit was charged with acquisition costs of MSEK 4.2. · PROFIT AFTER TAX amounted to MSEK 30.3 (13.1). · PROFIT AFTER TAX PER SHARE was SEK 3.32 (1.44). · CHANGE IN CASH AND CASH EQUIVALENTS amounted to MSEK 797,8 (21.5). Probi paid dividends of MSEK 9.1 (7.7). ACCUMULATED 2016 · NET SALES amounted to MSEK 249.5 (179.8). · OPERATING PROFIT[1] totalled MSEK 86.7 (59.4). Operating profit was charged with acquisition costs of MSEK 11.7. ·

    Q2 2016: Continued healthy growth and a transforming acquisition

    SECOND QUARTER OF 2016 · NET SALES amounted to MSEK 73.3 (59.0). · OPERATING PROFIT totalled MSEK 20.7 (15.7). Operating profit includes acquisition costs in the amount of 7.5 MSEK · PROFIT AFTER TAX amounted to MSEK 17.1 (10.8). · PROFIT AFTER TAX PER SHARE was SEK 1.87 (1.19). · CHANGES IN CASH AND CASH EQUIVALENTS amounted to MSEK 16.4 (neg: 5.1). Probi paid dividends of MSEK 9.1 (7.7). ACCUMULATED 2016 · NET SALES amounted to MSEK 160.3 (127.9). · OPERATING PROFIT totalled MSEK 56.0 (43.0). Operating profit includes acquisition costs in the amount of 7.5 MSEK

    Q1 2016: HIGHEST NET SALES TO DATE FOR A SINGLE QUARTER: MSEK 87.0 (68.9)

    First quarter of 2016: · NET SALES amounted to MSEK 87.0 (68.9). · OPERATING PROFIT totalled MSEK 35.3 (27.3). · PROFIT AFTER TAX amounted to MSEK 26.9 (22.4). · PROFIT AFTER TAX PER SHARE was SEK 2.95 (2.45). · CASH FLOW amounted to MSEK 10.0 (18.5).  Significant events during the first quarter: · Probi Järn®, Probi’s product to increase iron absorption, was launched in Sweden. · Launch of Probi’s products in Singapore. · Probi acquired license for new probiotic strains for food applications from Swedish company Probac. Significant events after the close

    Q4 2015 - 60% GROWTH AND INCREASED OPERATING MARGIN FOR FULL-YEAR 2015

    FOURTH QUARTER OF 2015 · NET SALES amounted to MSEK 35.9 (39.9). · OPERATIG PROFIT totalled MSEK 3.7 (6.6). · PROFIT AFTER TAX amounted to MSEK 2.7 (5.4). · PROFIT AFTER TAX PER SHARE was SEK 0.30 (0.59). · CASH FLOW amounted to MSEK 0.0 (10.6). ACCUMULATED 2015 · NET SALES amounted to MSEK 215.7 (135.2). · OPERATING PROFIT totalled MSEK 63.1 (27.0). · PROFIT AFTER TAX amounted to MSEK 49.0 (21.8). · PROFIT AFTER TAX PER SHARE was SEK 5.38 (2.39). · CASH FLOW amounted to MSEK 34.8 (16.9). SIGNIFICANT EVENTS DURING THE FOURTH QUARTER: · Probi

    Q3 2015 - NEW FOOD PRODUCT LAUNCH IN SOUTH KOREA

    THIRD QUARTER OF 2015 • NET SALES amounted to MSEK 51.9 (37.1). • OPERATING PROFIT totalled MSEK 16.3 (9.0). • PROFIT AFTER TAX amounted to MSEK 13.1 (7.1). • PROFIT AFTER TAX PER SHARE was SEK 1.44 (0.77). • CASH FLOW amounted to MSEK 21.5 (3.3).           ACCUMULATED 2015 • NET SALES amounted to MSEK 179.8 (95.3). • OPERATING PROFIT totalled MSEK 59.4 (20.5). • PROFIT AFTER TAX amounted to MSEK 46.3 (16.4). • PROFIT AFTER TAX PER SHARE was SEK 5.08 (1.80). • CASH FLOW amounted to MSEK 34.8 (6.3). SIGNIFICANT EVENTS DURING THE THIRD QUARTER: • Peter

    Q2 2015 - NET SALES ROSE 85% TO MSEK 59.0, COMPARED WITH THE SECOND QUARTER OF 2014

    SECOND QUARTER OF 2015• NET SALES amounted to MSEK 59.0 (31.9).• OPERATING PROFIT totalled MSEK 15.7 (5.3).• PROFIT AFTER TAX amounted to MSEK 10.8 (4.3).• PROFIT AFTER TAX PER SHARE was SEK 1.19 (0.47).• CASH FLOW was a negative MSEK 5.1 (neg: 0.6). Probi paid dividends of MSEK 7.7 (6.8). ACCUMULATED 2015• NET SALES amounted to MSEK 127.9 (58.3).• OPERATING PROFIT totalled MSEK 43.0 (11.5).• PROFIT AFTER TAX amounted to MSEK 33.2 (9.3).• PROFIT AFTER TAX PER SHARE was SEK 3.64 (1.03).• CASH FLOW amounted to MSEK 13.4 (3.0). Probi paid dividends of MSEK 7.7 (6.8).

    Net sales rose MSEK 42.5 compared with the first quarter of 2014

    FIRST QUARTER 2015•    NET SALES amounted to MSEK 68.9 (26.4). •    OPERATING PROFIT totalled MSEK 27.3 (6.1). •    PROFIT AFTER TAX amounted to MSEK 22.4 (5.0). •    PROFIT AFTER TAX PER SHARE was SEK 2.45 (0.55). •    TOTAL CASH FLOW amounted to MSEK 18.5 (3.6). SIGNIFICANT EVENTS DURING THE FIRST QUARTER:•    Probi secured a record order valued at MSEK 17 from US company NBTY, which was delivered in the first quarter.•    Probi entered into long-term research collaboration with Wageningen University in the Netherlands.•    The partnership agreement with DKSH was

    NET SALES ROSE 54% TO MSEK 37.1 IN THE THIRD QUARTER

    THIRD QUARTER OF 2014• NET SALES amounted to MSEK 37.1 (24.1).• OPERATING PROFIT totalled MSEK 9.0 (4.5).• PROFIT AFTER TAX amounted to MSEK 7.1 (3.7).• PROFIT AFTER TAX PER SHARE was SEK 0.77 (0.41).•CASH FLOW amounted to MSEK 3.3 (4.2).  ACCUMULATED 2014• NET SALES amounted to MSEK 95.3 (76.1).• OPERATING PROFIT totalled MSEK 20.5 (15.1).• PROFIT AFTER TAX amounted to MSEK 16.4 (12.4).• PROFIT AFTER TAX PER SHARE was SEK 1.80 (1.36).•CASH FLOW amounted to MSEK 6.3 (4.1). Probi paid dividends of MSEK 6.8 (6.8).  SIGNIFICANT EVENTS DURING THE THIRD QUARTER:•

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media